The Uveal Melanoma drugs in development market research report provides comprehensive information on the therapeutics under development for Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Uveal Melanoma. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued products.

GlobalData tracks 86 drugs in development for Uveal Melanoma by 69 companies/universities/institutes. The top development phase for Uveal Melanoma is phase ii with 44 drugs in that stage. The Uveal Melanoma pipeline has 79 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Uveal Melanoma pipeline products market are: Bristol-Myers Squibb, Pfizer and Lyvgen Biopharma.

The key targets in the Uveal Melanoma pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Cells Expressing Melanoma Antigen Preferentially Expressed In Tumors (Cancer/Testis Antigen 130 or Opa Interacting Protein 4 or OIP4 or Preferentially Expressed Antigen Of Melanoma or PRAME), and Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4).

The key mechanisms of action in the Uveal Melanoma pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with five drugs in Phase II. The Uveal Melanoma pipeline products include 17 routes of administration with the top ROA being Intravenous and 15 key molecule types in the Uveal Melanoma pipeline products market including Small Molecule, and Monoclonal Antibody.

Uveal Melanoma overview

Uveal melanoma, the most common intraocular tumor, is a disease in which malignant (cancer) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include a dark spot on the iris, glaucoma, eye pain, and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation, and proton therapy.

For a complete picture of Uveal Melanoma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.